The RANKL/RANK system as a therapeutic target for bone invasion by oral squamous cell carcinoma

The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells

(2011) M. Shin et al.   CARCINOGENESIS

The cellular and molecular mechanisms of bone invasion by oral squamous cell carcinoma

(2011) E Jimi et al.   ORAL DISEASES

Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion

(2011) Guenther G. Steger et al.   Therapeutic Advances in Medical Oncology

Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer

(2010) Ezra E.W. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Denosumab-related osteonecrosis of the jaws

(2010) A. Kyrgidis et al.   OSTEOPOROSIS INTERNATIONAL

Roles of Interleukin-6 and Parathyroid Hormone-Related Peptide in Osteoclast Formation Associated with Oral Cancers

(2009) Kou Kayamori et al.   AMERICAN JOURNAL OF PATHOLOGY

Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy

(2009) S. Choi et al.   JOURNAL OF DENTAL RESEARCH

Immunohistochemical expression of RANKL, RANK, and OPG in human oral squamous cell carcinoma

(2009) Fu-Hsiung Chuang et al.   JOURNAL OF ORAL PATHOLOGY & MEDICINE

Oral squamous cell carcinoma cells modulate osteoclast function by RANKL-dependent and -independent mechanisms

(2008) Takeyuki Tada et al.   CANCER LETTERS

Recent Advances in Head and Neck Cancer

(2008) Robert I. Haddad et al.   NEW ENGLAND JOURNAL OF MEDICINE

RANK ligand as a therapeutic target for bone metastases and multiple myeloma

(2007) G. David Roodman et al.   CANCER TREATMENT REVIEWS